Equities research analysts expect that Veritone will post ($5.37) earnings per share for the current fiscal year. The stock is a Buy among 1 brokerage firms polled by Factset Research.

Veritone, Inc. has a 12-month low of $7.76 and a 12-month high of $60.00. Craig Hallum assumed coverage on Veritone in a research note on Tuesday, June 6th.

On August 11, 2017 Roth Capital initiated coverage on VERI setting a rating of “Buy”. Wunderlich reaffirmed a buy rating and set a $18.00 price target on shares of Veritone in a report on Wednesday, June 21st. Whereas 0 of them predict the stock is a hold. The firm’s market capitalization is $841.78 million.

It is now trading at $57.12 which is quite a bit higher than the 50 day moving average of $15.74 and which is significantly higher than the 200 day moving average of $13.56.

Looking forward, the company’s quarterly earnings are expected to come at $0.26 in the three months through September 2017 and $0.25 in the quarter ending December 2017, reflecting 8.33% and 4.17% growth, respectively. The stock has a consensus rating of Buy and a consensus target price of $16.44. They issued a buy rating and a $13.20 price target for the company. Analysts are forecasting earnings of $-0.59 on a per share basis this quarter. The forecast of 4 surveyed investment analysts covering the stock advises investors to Buy stake in the company.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Week Herald and is owned by of Week Herald.

Quantum-Veritone Artificial Intelligence Solution Wins IBC2017 NewBay Best of Show Award. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of USA and worldwide trademark and copyright legislation.

A number of other institutional investors have also recently made changes to their positions in VERI. The correct version of this piece of content can be read at https://www.truebluetribune.com/2017/09/26/veritone-inc-veri-given-a-23-00-price-target-at-northland-securities.html.

Jaguar Health, Inc. (NASDAQ:JAGX) is worth US$33.04 Million and has recently risen 4.79% to US$0.41. Finally, White Pine Capital LLC purchased a new stake in shares of Veritone in the second quarter valued at approximately $583,000. Spark Investment Management LLC bought a new stake in Veritone during the 2nd quarter worth approximately $126,000. Northern Trust Corp bought a new stake in Veritone during the 2nd quarter worth approximately $269,000. The Company’s platform unlocks the power of cognitive computing to transform unstructured audio and video data and analyze it in conjunction with structured data in a seamless, automated manner to generate actionable intelligence. Perkins Capital Management Inc. acquired a new stake in Veritone in the 2nd quarter valued at about $498,000.